Key Takeaways Amicus Therapeutics' 2025 earnings are projected to rise 29.2% year over year.Micron's fiscal 2026 earnings are expected to surge 100% year over year.General Dynamics' 2025 earnings are forecasted to climb 11.7% from the prior-year level.Investor sentiments are bullish of late despite tariff policies resulting in higher inflation. Last month, the Federal Reserve lowered interest rates for the first time this year amid a continued deterioration in the labor market. Amid such a backdrop, retail ...

Key Takeaways Amicus' Galafold recorded $233.1M in H1 2025 sales, up 11% year over year.Label expansion and global approvals have boosted Galafold's revenue growth in recent times.Teva settlement blocks Galafold generics in the United States until January 2037.Amicus Therapeutics’ (FOLD) lead product, Galafold (migalastat), has been driving the majority of the company’s revenues. The drug remains a key top-line driver for the company.Galafold is the first oral precision medicine approved for treating patien ...

Live Chat on The Biotech Forum sees frequent discussion of specific covered call trades. To see what covered call trades I am currently executing along with a model portfolio of attractive biotech stocks, just initiate your free trial into The Biotech Forum by clicking HERE .In this column, I am going to highlight three of my favorite biotech stocks that are trading under $10.00 a share. First, I am going to put a few caveats in place. One of primary ones are these are stocksBret leads the investing group T ...

Key Takeaways RIGL's Tavalisse drove $68.5M sales in H1 2025, up 44% year over year, driving top-line growth.RIGL raised its 2025 revenue outlook to $270-$280M on strong performance across its marketed products.FOLD's Galafold posted $233.1M H1 2025 sales, up 11% year over year, with patent protection to 2038.Both Rigel Pharmaceuticals (RIGL) and Amicus Therapeutics (FOLD) are developing and commercializing treatments for rare medical conditions where existing therapies are limited, with the goal of establi ...

Amicus Therapeutics (FOLD) shares soared 6.4% in the last trading session to close at $8.48. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 7.7% gain over the past four weeks.The price rise can be attributed to growing investor optimism related to the strong uptake of the company’s lead product, Galafold and the combination drug, Pombiliti + Opfolda. In the first six months of 2025, Galafold generated sales worth $233.1 million, ...

公司评级与目标价 - Needham将Amicus Therapeutics评级从持有上调至买入 目标价设定为14美元[2] - 公司股价今日上涨约5%[2] 核心产品管线价值 - 公司肾脏疾病治疗项目DMX-200被市场低估[2] - DMX-200项目目前处于临床二期阶段[2]

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly.Top 5 Upgrades: RBC Capital upgraded Nike (NKE) to Outperform from Sector Perform with a price target of $90, up from $76. The firm sees a "steeper revenue recovery" for Nike than Street estimates reflect with new product contribution and World Cup selling. Needham upgraded Amicus (FOLD) to Buy from Hold with a $14 price targ ...

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.Needham analyst Gil Blum upgraded Amicus Therapeutics, Inc. FOLD from Hold to Buy and announced a $14 price target. Amicus Therapeutics shares closed at $7.97 on Wednesday. See how other analysts view this stock.RBC Capital analyst Walter Spracklin upgraded the rating for CSX Corporation CSX from Sector Perfo ...

公司介绍 - 摩根士丹利生物技术分析师Max Skor主持Amicus Therapeutics公司会议 [1] - Amicus Therapeutics公司参会人员包括首席商务官Sébastien Martel和首席开发官Jeffrey Castelli [1] 会议安排 - 会议开场环节安排公司高层进行高层要点介绍 [2] - 会议为不熟悉Amicus Therapeutics公司的参会者提供公司概况介绍环节 [2]

Amicus Therapeutics (NasdaqGM:FOLD) FY Conference September 09, 2025 03:20 PM ET Company ParticipantsMaxwell Skor - VP - Biotech Equity ResearchSébastien Martel - Chief Business OfficerJeffrey Castelli - Chief Development OfficerMaxwell SkorI'm Max Score, a biotech analyst with Morgan Stanley. I'm happy to be hosting Amicus Therapeutics. With us today is Sebastian Martell, chief business officer Jeff Castelli, chief development officer. But before we dive in, I just want to note for important disclosures, p ...